ArticleCureus2025
Hearing Loss in Leucine-Rich Glioma-Inactivated 1 Encephalitis: Cochlear Implantation Considerations.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Transcriptomic meta-analysis identifies dysregulated pathways and potential therapeutic targets in Vestibular Schwannoma.PloS one · 2026Pooled it
- Hearing Loss in Neuromyelitis Optica Spectrum Disorder: Case Report and Systematic Review.Journal of clinical medicine · 2026Review
- Vitamin D and sudden sensorineural hearing loss: emerging associations, mechanistic insights, and prospects for precision medicine - a review.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leucine-rich glioma-inactivated 1 (LGI-1) antibody-associated autoimmune encephalitis is a rare neurologic disorder primarily presenting with memory impairment, behavioral changes, and seizures. Auditory symptoms, particularly sensorineural hearing loss (SNHL), are uncommon but may occur due to LGI-1 expression in auditory pathways. A 78-year-old male with a prior diagnosis of LGI-1 autoimmune encephalitis presented with progressive bilateral SNHL and frequent falls. His audiogram revealed significant deficits in high frequencies and impaired speech recognition without evidence of middle ear pathology, affecting quality of life. Neuroimaging showed chronic white matter lesions consistent with LGI-1 encephalitis. Cochlear implantation was discussed as a potential rehabilitative treatment. This case underscores SNHL as a potentially significant yet rare manifestation of LGI-1 antibody-associated autoimmune encephalitis. The patient's profound hearing loss suggests an autoimmune mechanism affecting both central auditory and peripheral cochlear pathways. Cochlear implantation, although not widely studied in autoimmune-mediated auditory disorders or trialed in this case, emerged as a promising option for rehabilitation, necessitating further investigation into its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.